Antonio Jimeno
Physician at Joliet Way, Englewood, CO
License number
Colorado 47300
Issued Date
Dec 18, 2008
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
5250 S Joliet Way S Joliet Way, Englewood, CO 80111
Personal information
See more information about Antonio Jimeno at radaris.comName
Address
Phone
5250 S Joliet Way, Englewood, CO 80111
Professional information
See more information about Antonio Jimeno at trustoria.com
On01910.Na Enhances Chemotherapeutic Agent Activity In Drug-Resistant Tumors
On01910.Na Enhances Chemotherapeutic Agent Activity In Drug-Resistant Tumors
US Patent:
2011020, Aug 18, 2011
Filed:
Apr 17, 2008
Appl. No.:
12/988471
Inventors:
Antonio Jimeno - Englewood CO, US
Manuel Medina Hidalgo - Baltimore MD, US
Manuel Medina Hidalgo - Baltimore MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 31/7088, A61K 31/198, A61K 31/7076, A61K 31/7068, A61K 31/513, A61K 31/7072, A61K 31/551, A61K 31/52, A61P 35/00
US Classification:
514 44 R, 514562, 514 47, 514 46, 514 49, 514274, 514 50, 514221, 51426331
Abstract:
The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction or stabilization of at least one sign or symptom of cancer.
Methods To Correct Gene Set Expression Profiles To Drug Sensitivity
Methods To Correct Gene Set Expression Profiles To Drug Sensitivity
US Patent:
2009022, Sep 3, 2009
Filed:
Feb 17, 2009
Appl. No.:
12/372373
Inventors:
Manuel Hidalgo - Baltimore MD, US
Antonio Jimeno - Englewood CO, US
Aik Choon Tan - Highlands Ranch CO, US
Antonio Jimeno - Englewood CO, US
Aik Choon Tan - Highlands Ranch CO, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 31/7068, C12Q 1/68, C40B 30/00, A61K 31/337, A61K 31/4353, A61P 35/00
US Classification:
514 49, 435 6, 506 7, 514449, 514291
Abstract:
The present invention comprises a treatment approach based on gene set-expression signatures that systematically connects a sample to a profile from a reference database to extrapolate the most effective therapeutic agent. Further disclosed are methods to optimize combination treatments.
Synthesis Of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (Bpu) Sulfur Analogs
Synthesis Of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (Bpu) Sulfur Analogs
US Patent:
2009009, Apr 16, 2009
Filed:
Sep 16, 2008
Appl. No.:
12/211492
Inventors:
Saeed R. Khan - Owlings Mills MD, US
Gurulingappa Hallur - Owlings Mills MD, US
Manuel Hidalgo - Baltimore MD, US
Antonio Jimeno - Englewood CO, US
Gurulingappa Hallur - Owlings Mills MD, US
Manuel Hidalgo - Baltimore MD, US
Antonio Jimeno - Englewood CO, US
International Classification:
A61K 31/505, C07D 239/38, A61K 31/513, C07D 239/34, A61P 35/00
US Classification:
514274, 544316
Abstract:
This invention provides a series of BPU analogues; their synthesis and evaluated biological activity. BPU sulfur analogues were found to possess up to 20 fold increased potency, when compared to compound 1, in various cancerous cell lines.
Synthesis Of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (Bpu) Sulfur Analogs
Synthesis Of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (Bpu) Sulfur Analogs
US Patent:
2010011, May 6, 2010
Filed:
May 26, 2009
Appl. No.:
12/471585
Inventors:
Saeed R. Khan - Owlings Mills MD, US
Gurulingappa Hallur - Owlings Mills MD, US
Manuel Hidalgo - Baltimore MD, US
Antonio Jimeno - Englewood CO, US
Gurulingappa Hallur - Owlings Mills MD, US
Manuel Hidalgo - Baltimore MD, US
Antonio Jimeno - Englewood CO, US
International Classification:
A61K 31/505, C12N 5/00, C07D 239/38
US Classification:
514274, 435375, 544316
Abstract:
A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6n and 7d were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell lines. 6n was more effective than compound 1 in causing apoptosis of MCF-7 cells. When compared to other drugs with a similar mechanism of action, 6n retained significant ability to inhibit tubulin assembly, with an IC50 of 2.1 μM.